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Abstract 
Objectives: Use of certain drugs is the most common aetiology of xerostomia. Systemic sialogogues provide a 
longer effect than topic ones, but also induce relevant side effects. Topical sialogogues, as malic acid, allow a safe 
use as they induce no systemic side-effects or pharmacological interactions, being especially interesting in cases 
of mild hyposalivation and oral dryness, mainly the chronic use of xerostomizing drugs. The aim of this study 
was to evaluate the clinical effect of 1% malic acid in patients affected by xerostomia due to antihypertensives or 
antidepressants.
Study Design: 10 patients with drug-induced xerostomia were prospectively evaluated before and after using malic 
acid spray during three weeks. Xerostomia Inventory (XI) was used to evaluate subjective improvement. Unstimu-
lated and stimulated salivary flow rates were determinated.
Results: Severity significantly decreased, from 38.22 to 31.00 points (p = 0.011) after using the product. 77.8% of 
subjects did not complain about xerostomia at the end and 66.6% achieved an improvement > 6 points. Unstimula-
ted flow rate singnificantly increased, from 0.163 to 0.226 mL/min (p = 0.021) at the third week.
Conclusions: 1% malic acid spray induces some improvement in the management of mild and reversible xerosto-
mia. Carrying out of randomized controlled trials is justified according to this study.
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Introduction 
The association of a decrease of salivary flow rates and 
the altered composition of saliva, as a consequence of 
salivary gland hypofunction leads, in most cases, to sub-
jectives complaints or oral dryness (xerostomia). Saliva 
is indispensable in maintaining oral health (1). Decrea-
ses in the amount of saliva or its quality may produce 
difficulties in swallowing, alteration of the taste percep-
tion, or a higher risk of developing oral diseases as ca-
ries, C. albicans (Candida albicans) infection (2) and 
also periodontal disorders (3).
Use of certain systemic drugs is the most common aetio-
logy of xerostomia (4). Drug-induced xerostomia is tem-
porary, lasting to the end of pharmacological treatment, 
and usually presenting mild-to-moderate severity. It has 
been described more than 500 drugs, among 42 phar-
macological groups, inducing oral dryness (5). Other 
aetiologies as head and neck radiotherapy or Sjögren’s 
syndrome are related with severe hyposalivation, but its 
prevalence is not as frequent as intake of these drugs.
Antidepressants are the most important drugs inducing 
xerostomia, mainly tricyclic antidepressants (6). The-
refore, selective serotonin reuptake inhibitors (SSRI) 
has also been related with xerostomia, specially when 
combined with benzodiazepines (7). Diuretics are also 
one of the most xerostomizing drugs. Chronic intake of 
diuretics increases nearly six times the incidence of xe-
rostomia (6). Other antihypertensives as beta-blokers (8) 
or angiotensine-converting enzyme inhibitors have also 
been reported as xerostomic drugs, producing dry mouth 
in about 13% of patients (9).
There is a wide spectrum of approaches in the mana-
gement of xerostomia, from the classical ones, either 
salivary stimulants or saliva substitutes and artificial sa-
livas, to the most recent as lingual nerve electrostimula-
tion (10), sodium channel blockers or acupuncture (11).
Available treatments nowadays are not truly effective. 
Thus, an ideal approach of treatment should be long-
lasting (xerostomia worsen specially during the night), 
salivary stimulant, leading to normal salivary flow rates, 
with a topic activity, without side-effects (systemic or 
caries) and accepted by the patient. Systemic sialogo-
gues provide a longer effect than topic ones. Neverthe-
less, these drugs induce relevant side effects due to the 
parasympathetic induction as nausea, rhinitis, sweating, 
flushing and frequent polyuria (12). Topical salivary sti-
mulants, as organic acids (malic, citric or ascorbic acid) 
have a very transient effect. Furthermore, these substan-
ces allow a safe use as they induce no systemic side-
effects or pharmacological interactions, being especially 
interesting in those cases of mild hyposalivation and oral 
dryness, mainly the chronic use of xerostomizing drugs.
The objective of this study was to evaluate the clinical 
effect of 1% malic acid, as a topical sialogogue, in pa-
tients affected by drug-induced xerostomia due to chro-
nic treatment with antihypertensives or antidepressants.
Material and Methods
This study has been accepted by the university of Grana-
da Ethics Committee on Research. All the measurements 
and intervention were undertaken with the understanding 
and written consent of each subject. The investigation 
was designed as a single-blinded pilot study including 
10 patients suffering for xerostomia as a consequence of 
chronic administration (more than two months prior to 
the intervention) of antidepressive and/or antihyperten-
sive medication (diuretics, beta-blokers and/or angioten-
sin-converting-enzyme inhibitors).
Patients recruitment and intervention
Patients with xerostomia attending to the university 
of Granada School of Dentistry were evaluated. Re-
cruitment of patients was made consecutively, including 
subjects in treatment with antidepressive or antihyper-
tensive drugs and excluding any other aetiologies of 
hyposalivation (Sjögren’s syndrome, radiotherapy, dia-
betes,…). There was no restriction about age, gender 
and oral conditions (edentulism, denture wearers,…) 
After performing anamnesis on recruited subjects, the 
following question was presented to each patient. “How 
often do you feel dry mouth?” Response options were 
“never”, “occasionally”, “frequently” or ”always”. On 
each occasion, those who said “frequently” or “always” 
were considered xerostomia (13). 
The intervention consists on the at-home application of 
a topical sialogogue containing 1% malic acid (Xeros 
Dentaid Spray©, Dentaid, Barcelona, Spain) during three 
weeks. Each patient used the product as many times as 
they consider necessary. The spray was presented to the 
subjects without any brand name. Thus, the patients did 
not know which product they were being treated with 
(single-blinded).
Measures
Xerostomia Inventory (XI) test was used to obtain subjec-
tive information about the severity of xerostomia before 
and after treatment with malic acid (14). This 11-item 
survey is considered a valid tool to evaluate changes in 
xerostomia severity after an intervention (15,16). Higher 
scores of XI mean worse xerostomia. A decrease in XI 
score ≥ 6 points from baseline was accepted as a partial 
response (PR). Differences <6 points but >3 points were 
defined as minor response (MR). No response (NR) was 
defined as a decrease of <3 points after intervention 
(15).
As secondary measurements, whole salivary flow rates 
were assessed in all patients. Saliva was collected on 
a pre-weighed 20-mL plastic container. Unstimulated 
flow rate was obtained by the spit method every 30 se-
conds during 15 minutes. Collection tubes were weig-
hed (in 0.001g) using a precision scale (Cobos M-150, 
Cobos, Barcelona, Spain) and expressed as mL/min, as 
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previously described (17). Stimulated whole saliva was 
obtained by chewing 1-g piece of paraffin wax during 
over a period of 6 minutes. Saliva collected during the 
first minute was discarded, and then collected into the 
container every 30 seconds (18). Either XI or sialome-
tries were assessed always at the same time (09:00 a.m. 
to 11:00 a.m) to avoid any circadian variation. Before 
the evaluation, patients were told not to eat, nor drink, 
nor smoke, nor brush their teeth from one hour prior the 
visit.
Statistical analysis
All the analyses were performed using SPSS software 
v17.0 (SPSS INC., Chicago, IL, USA). The primary en-
dpoint was to test for differences between XI scores at 
baseline and at the end of the study (week 3). Wilcoxon 
signed rank test was applied as the data were not nor-
mally distributed. Same test was used for the analysis of 
salivary flow rates. Level of significance for all tests was 
set at 0.05 and 90% power.
Results
A total of 10 subjects (9 female, 1 male) with drug-indu-
ced xerostomia were recruited in our study. One of the 
patients increased three times the dosage of xerostomic 
drug (from 25 mg/d maprotiline to 75 mg/d maprotiline) 
during the follow-up. Thus, this subject was discarded 
for the statistical analysis, resulting in a final sample of 
9 subjects, size enough for the preliminary study we ex-
pected. Three patients were being treated with antide-
pressants, five with antihypertensives, and one patient 
were receiving antidepressive and antihypertensive 
drugs (Table 1). Mean age of the sample was 50.33 ± 
7.31 years-old and participants used the sialogogue 3.67 
± 1.41 times per day, needing a new application after 
406 ± 397 min as shown in Table 2.
At baseline, mean XI score was 38.22 ± 7.80 points. At 
the end of the study, XI score significantly decreased to 
31.00 ± 7.22 points (p = 0.011), resulting a reduction of 
7.22 ± 5.52 points (Figure 1). 88.9% of patients eviden-
Subject Drugs
1 Amitriptyline, acetaminophen.
2* Maprotiline, acetaminophen, omeprazo-le, naproxen, levothyroxine.
3 Telmisartan, chondroitin sulfate.
4 Torasemide, ebastine, omeprazole, alpra-zolam.
5 Paroxetine, levothyroxine, alprazolam.
6 Indapamide, levothyroxine, simvastatin.
7 Chlortalidone, carvedilol, tamsulosin, chondroitin sulfate, bromazepam.
8 Citalopram, captopril, levothyroxine, acetylsalicylic acid, omeprazole.
9 Citalopram, ibuprofen, pantoprazole
10 Bisoprolol
Bold: xerostomic drugs: antidepressants or antihypertensives (diu-
retics, beta-blokers and/or angiotensin-converting-enzyme inhibi-
tors)
*: Discarded patient
Table 1. Chronic pharmacological treatment of the patients. 
Sample size (N) 9
Age (years) 50.33 (7.31)
Gender
Male 1 (11.1 %)
Female 8 (88.9 %)
XI score
Baseline 38.22 (7.80)
Final (three weeks) 31.00 (7.22) * p = 0.011
XI difference 7.22 (5.52)
Number of applications/
day 3.67 (1.41)
Effect duration (min) 406 (397)
Mean (standard deviation).
*: p < 0.05
Table 2. Age, gender, XI score and effect duration of the participants.
Fig. 1. Mean and standard deviations of XI score of the participants. 
Differences greater than 6 points are considered “partial response” 
to the product. Blue line shows the symptom threshold (14.5 points).
Fig. 2. Individual XI score. Individual progress of each participant 
in the study
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ced some improvement after the treatment with 1% ma-
lic acid. 66.6% of patients achieved an improvement > 
6 points (partial response). None of the participants got 
worse their initial situation after the intervention. 77.8% 
of patients did not complaint about xerostomia after be-
ing treated with the sialogogue (Figure 2).
Salivary flow rates also improved after treatment. Uns-
timulated flow rate (UFR) significantly increased from 
0.163 mL/min at baseline to 0.226 mL/min (p = 0.021) 
at the third week (Table 3). Stimulated flow rate (SFR) 
also increased from 0.574 mL/min to 0.734 mL/min (p = 
0.051), but the difference was not statistically significant 
(Figure 3). 
< 0.5 mL/min) (19). Half of these duplicated their rates 
after three weeks. The other half, as patients with SFR 
> 0.5 mL/min, increased their rates in a minor extension 
(5.7% to 19.5%) or slightly decreased (-6.4% to -8.4%).
Discussion
Topical treatment with 1% malic acid, when applied onto 
the oral mucosa, is shown to improve the oral dryness 
felt by the patients and also their unstimulated flow ra-
tes, based on previous results. The use of acid substances 
to induce the salivation reflex is not recent. However, 
chronic application of these sialogogues, as citric acid, 
is related with a higher risk of caries, due to de acidic 
dental erosion over the dentin (20). In 1980, Anneroth 
et al. (21) found similar effects after using 0,06 mg as-
corbic or malic acid chewing-gums, containing sorbitol 
and mannitol. These products were dropped out because 
of their demineralizing effect on human dentin, not only 
related with high doses of acid, but also to the product 
appearance (chewable) which allowed a prolonged con-
tact onto the dental surfaces.
Recent research reported that a suitable administration 
format, as spray format, which allows a fast and tem-
porary contact on the oral mucosa, combined with a 
suitable formulation could decrease the demineralizing 
potential as the salivary stimulant effect remains unchan-
ged (22,23). The use of 4.7% malic acid spray, combined 
with fluorures/xylitol, on 60 healthy subjects induced a 
significant drop in salivary pH levels which recovered 
Baseline Final (three weeks)
Unstimulated (mL/min) 0.163 (0.101) 0.226 (0.088) * p = 0.021
Stimulated (mL/min) 0.574 (0.292) 0.734 (0.245) p = 0.051
Mean (standard deviation).
*: p < 0.05
Table 3. Unstimulated and stimulated salivary flow rates of the participants. 
Fig. 3. Mean and standard deviations of salivary flow rates. Blue 
(unstimulated) and green (stimulated) lines show the hyposalivation 
threshold.
A third of participants were initially categorized as hy-
posalivation patients (UFR < 0.1 mL/min) (19). All of 
them exceeded the hyposalivation threshold after the 
intervention, with relevant increases (multiplying from 
two to seven times) of their initial rates. The other two-
thirds had a reduced salivation (between 0.1 and 0.3 mL/
min) at the beginning. They improved their unstimulated 
rates, but the increases were between 13% and 58%, ex-
cept one of them who suffered a reduction of 21% (Fi-
gure 4).
Regarding stimulated rates, 44.4% of the participants 
were initially considered as hyposalivation patients (SFR 
Fig. 4. Individual progress of unstimulated flow rates of each parti-
cipant. Black line shows hyposalivation threshold (0.100 mL/min). 
Percentages on the bars indicate increase/decrease after using the 
product.
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after 20 minutes. Although pH decreased immediately 
after the application of an acid, when administering this 
acidic xylitol-fluoride-containing salivary stimulant, 
minimum pH did not reach the hydroxyapatite critical 
level (pH = 5,5), while a no xylitol-fluoride-containing 
stimulant reached a pH score lower than 5,5 (24). Thus, 
combination of malic acid with xylitol/fluorides on spray 
seems to be a safe option as topical sialogogue.
Oral dryness is a common complaint we often can find 
among older adults in dental office. There is a wide 
spread of etiologies, different degrees of severity and re-
versible/irreversible course of xerostomia. Also there is 
available a large spectrum of different treatments in the 
management of xerostomia. Thorough diagnosis of the 
underlying etiology and salivary hypofunction is very 
important in order to choose the best treatment option 
in each patient, as each approach provides advantages 
and disadvantages and, nowadays, none of them is truly 
effective.
Acidic xylitol-fluoride-containing salivary stimulants 
are an interesting option in the management of mild and 
reversible xerostomia, mainly due to xerostomic drugs. 
These products, used as topical sialogogues, provides a 
short-term effect increasing unstimulated flow rates im-
mediately and reaching basal levels after 20 minutes (24) 
although patients do not feel the need of a new applica-
tion until six to seven hours later, based on this prelimi-
nary study. Radiotherapy on head and neck or Sjögren’s 
syndrome are less frequent etiologies, but they are much 
more present in the literature because of their severity 
and irreversible degenerative processes over salivary 
glands. Topical stimulants of the salivation may not be 
the correct choice in these cases, since it is necessary 
a stronger induction through systemic administration, 
mainly parasympathomimetic drugs as pilocarpine or 
cevimeline among others (25). These drugs provides a 
more long-lasting effect, but also inducing relevant side 
effects, as flushing, sweating or nausea, so they should 
be administered with caution (12). Even when the resi-
dual salivary function is very low, it is recommended the 
use of salivary substitutes and artifitial salivas (26).
After reviewing the recent literature, it is found a large 
amount of papers about the efficacy and feasibility of 
different treatments, especially systemic stimulants and 
artificial salivas. However, we could hardly find scienti-
fic evidence about topical sialogogues and, always based 
on an objective approach, by determination of salivary 
flow rates. It is also necessary to evaluate the improve-
ment felt by the patient, by subjective approach. This po-
int of view is almost absent when studying the classical 
therapies (sialogogues and substitutes) (1,18), but often 
appears in those papers evaluating new options as acu-
puncture (15,27,28). Among different available ques-
tionnaires and visual analogue scales (VAS), we used 
XI (14) since it is an easy, fast and no technical system. 
Furthermore, this 11-item questionnaire appears to be a 
valid multi-item method for measuring the severity of 
the symptoms of dry mouth in clinical and epidemiolo-
gic studies (16,29).
Results obtained show a significant increase of unstimu-
lated flow rate after using the stimulant, in acordance 
with da Mata et al. (24) when applied in healthy sub-
jects. There is no evidence about effectiveness of topical 
salivary stimulants in patients complaining for xeros-
tomia. In regards of subjective improvement, it cannot 
be found similar papers to compare. Researchers have 
left investigation about this topic because of the caries- 
inducing role of acidic susbtances when they were not 
well-formulated. Once improved this therapy, new re-
search is expected in the next years.
A preliminary study, as presented, is not evidence 
enough to state the effectiveness of the product. Further-
more, sample size was very small, nine patients. Pre-
sented results show some benefit after using malic acid 
spray. New effort is needed in carrying out a randomized 
controlled clinical trial, where this product will be com-
pared with a control (placebo) and using a larger sample 
size. Conclusions on this kind of research will help us to 
state if really malic acid may be an adequate approach of 
treatment in drug-induced xerostomia.
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